Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin’s Lymphoma

被引:0
作者
Atushi Yonezawa
Yuki Otani
Toshiyuki Kitano
Mayuko Mori
Sho Masui
Yui Isomoto
Masahiro Tsuda
Satoshi Imai
Yasuaki Ikemi
Masaya Denda
Yuki Sato
Shunsaku Nakagawa
Tomohiro Omura
Takayuki Nakagawa
Ikuko Yano
Makoto Hayakari
Akifumi Takaori-Kondo
Kazuo Matsubara
机构
[1] Kyoto University Hospital,Department of Clinical Pharmacology and Therapeutics
[2] Kyoto University,Graduate School of Pharmaceutical Sciences
[3] Kyoto University,Department of Hematology and Oncology, Graduate School of Medicine
[4] Kitano Hospital,Department of Hematology
[5] Kobe University Hospital,Department of Pharmacy
来源
Pharmaceutical Research | 2019年 / 36卷
关键词
carbohydrate chain; LC/TOF-MS; pharmacokinetics; rituximab; therapeutic monoclonal antibody;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 316 条
[1]  
Chan AC(2010)Therapeutic antibodies for autoimmunity and inflammation Nat Rev Immunol 10 301-316
[2]  
Carter PJ(2013)Antibody therapeutics in cancer Science 341 1192-1198
[3]  
Sliwkowski MX(2008)The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol 66 6-19
[4]  
Mellman I(2009)Production of therapeutic antibodies with controlled fucosylation MAbs 1 230-236
[5]  
Newsome BW(2003)The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J Biol Chem 278 3466-3473
[6]  
Ernstoff MS(2012)Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities MAbs 4 326-340
[7]  
Yamane-Ohnuki N(2013)Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models Mol Cancer Ther 12 2031-2042
[8]  
Satoh M(2014)Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 1101-1110
[9]  
Shinkawa T(2005)Control of recombinant monoclonal antibody effector functions by fc N-glycan remodeling in vitro Biotechnol Prog 21 1644-1652
[10]  
Nakamura K(2016)Effect of high mannose glycan pairing on IgG antibody clearance Biologicals 44 163-169